Zepbound

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Updated: December 10, 2025 Key takeaways LLY stock today: price, performance and valuation snapshot As of mid‑day trading on December 10, 2025, Eli Lilly (NYSE: LLY) is changing hands at around $980 per share, down slightly on the day and

10 December 2025

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company (NYSE: LLY) heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November

6 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock Today, 4 December 2025: Zepbound Price Cuts, Jaypirca FDA Win and New $1,200–$1,500 Targets

Date: 4 December 2025 Eli Lilly stock at a glance Eli Lilly and Company (NYSE: LLY) is trading around $1,030–$1,040 per share on 4 December 2025, down roughly 1% on the session after slipping from about $1,046 in the previous

4 December 2025

FDA Approvals · Investment Analysis · NYSE:LLY · Pharmaceuticals · Price Targets · Stock Market

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock

2 December 2025

Business News · Healthcare · Investing · NYSE:LLY · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

As of December 1, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,075 per share, giving the drugmaker a market capitalization of roughly $1.0–1.02 trillion and cementing its status as the first pharmaceutical company to enter the trillion‑dollar

1 December 2025

Company Analysis · Financial Forecasts · Investment · NYSE:LLY · Pharma News · Stock Market